hrp0089p3-p166 | Fat, Metabolism and Obesity P3 | ESPE2018

Assessment of Obesity in Children with Achondroplasia and Hypochondroplasia

Nakano Yukako , Kitaoka Taichi , Takeyari Shinji , Ohata Yasuhisa , Kubota Takuo , Ozono Keiichi

Introduction: Obesity is one of common complications in achondroplasia (ACH) and hypochondroplasia (HCH). Obesity can be a risk factor for excessive load on joints or lower spines in aged, worsen sleep apnea and develop a metabolic syndrome. Thus, it is critical to maintain their proper weight from early childhood. ACH specific growth charts and BMI has been used to evaluate their overweight and obesity. Due to disproportional short stature, the assessment by BMI could lead an...

hrp0092p1-168 | Bone, Growth Plate and Mineral Metabolism (1) | ESPE2019

Genotype-Phenotype Characteristics in Four Families of Type II Collagenopathy in Our Hospital

Yamamoto Kenichi , Kubota Takuo , Takeyari Shinji , Nakano Yukako , Nakayama Hirofumi , Fujiwara Makoto , Ohata Yasuhisa , Kitaoka Taichi , Miyoshi Yoko , Ozono Keiichi

Type II collagenopathy is a generic name of the skeletal dysplasia caused by COL2A1 gene, such as achondrogenesis type II, spondyloepiphyseal dysplasia (SEDC), spondyloepimetaphyseal dysplasia (SEMD). Since this is a rare disease, genotype-phenotype characteristics is still unclear. Here, we describe the genotype-phenotype characteristics of four families of type II collagenopathy in our hospital. Family 1: the proband was 2-year-old girl. She showed severe short stat...

hrp0086p1-p138 | Bone & Mineral Metabolism P1 | ESPE2016

Biochemical Parameters Associated with Serum Intact FGF23 Levels in Patients with X-Linked Hypophosphatemic Rickets

Kubota Takuo , Yamamoto Keiko , Miyata Kei , Takeyari Shinji , Yamamoto Kenichi , Nakayama Hirofumi , Fujiwara Makoto , Kitaoka Taichi , Takakuwa Satoshi , Ozono Keiichi

Background: Fibroblast growth factor 23 (FGF23) decreases renal phosphate reabsorption and serum 1,25-dihydroxyvitamin D [1,25(OH)2D] levels. X-linked hypophosphatemic rickets (XLH) is caused by mutations in the PHEX gene and accompanied by decreased serum inorganic phosphate (IP) and elevated serum FGF23 levels. Patients with XLH are generally treated with oral active vitamin D and phosphate, but some previous reports indicated that serum FGF23 levels increased with ...